Chemotherapy Induced Peripheral Neuropathy Treatment Market Report

Global and Region Chemotherapy Induced Peripheral Neuropathy Treatment Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Aug 02, 2022
  • PAGES：187
  • REPORT CODE：GMM987684
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The report details the trend, potential and market size of Chemotherapy Induced Peripheral Neuropathy Treatment market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of Chemotherapy Induced Peripheral Neuropathy Treatmentmarket, defines the market attractiveness level of Chemotherapy Induced Peripheral Neuropathy Treatment market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of Chemotherapy Induced Peripheral Neuropathy Treatment industry, describes the types of Chemotherapy Induced Peripheral Neuropathy Treatment market, the applications of major players and the market size, and deeply analyzes the current situation of the global Chemotherapy Induced Peripheral Neuropathy Treatment market and the development prospects and opportunities of Chemotherapy Induced Peripheral Neuropathy Treatment industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Chemotherapy Induced Peripheral Neuropathy Treatment market in Chapter 13.

    By Player:

    • Sova Pharmaceuticals Inc

    • Immune Pharmaceuticals Inc

    • Nemus Bioscience Inc

    • WinSanTor

    • Apexian Pharma

    • DermaXon LLC

    • PledPharma

    • Krenitsky Pharmaceuticals Inc

    • Aptinyx Inc

    • Kineta Inc

    • Regenacy Pharmaceuticals

    • Asahi Kasei Pharma Corp

    • PeriphaGen

    • Metys Pharmaceuticals AG

    • MAKScientific LLC

    By Type:

    • APX-3330

    • BR-297

    • Cannabidiol

    • Dimiracetam

    By End-User:

    • Platinum Agents

    • Taxanes

    • Vinca Alkaloids

    • Others

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 Chemotherapy Induced Peripheral Neuropathy Treatment Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 Chemotherapy Induced Peripheral Neuropathy Treatment Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 Chemotherapy Induced Peripheral Neuropathy Treatment Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 Chemotherapy Induced Peripheral Neuropathy Treatment Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise Chemotherapy Induced Peripheral Neuropathy Treatment Market Analysis and Outlook to 2022

    • 7.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Consumption (2017-2022)

    • 7.2 United States Chemotherapy Induced Peripheral Neuropathy Treatment Consumption (2017-2022)

    • 7.3 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Consumption (2017-2022)

    • 7.4 China Chemotherapy Induced Peripheral Neuropathy Treatment Consumption (2017-2022)

    • 7.5 Japan Chemotherapy Induced Peripheral Neuropathy Treatment Consumption (2017-2022)

    • 7.6 India Chemotherapy Induced Peripheral Neuropathy Treatment Consumption (2017-2022)

    • 7.7 South Korea Chemotherapy Induced Peripheral Neuropathy Treatment Consumption (2017-2022)

    8 Region and Country-wise Chemotherapy Induced Peripheral Neuropathy Treatment Market Analysis and Outlook to 2028

    • 8.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Consumption Forecast (2022-2028)

    • 8.2 United States Chemotherapy Induced Peripheral Neuropathy Treatment Consumption Forecast (2022-2028)

    • 8.3 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Consumption Forecast (2022-2028)

    • 8.4 China Chemotherapy Induced Peripheral Neuropathy Treatment Consumption Forecast (2022-2028)

    • 8.5 Japan Chemotherapy Induced Peripheral Neuropathy Treatment Consumption Forecast (2022-2028)

    • 8.6 India Chemotherapy Induced Peripheral Neuropathy Treatment Consumption Forecast (2022-2028)

    • 8.7 South Korea Chemotherapy Induced Peripheral Neuropathy Treatment Consumption Forecast (2022-2028)

    9 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Outlook by Types and Applications to 2022

    • 9.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global APX-3330 Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global BR-297 Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Cannabidiol Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global Dimiracetam Consumption and Growth Rate (2017-2022)

    • 9.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Platinum Agents Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Taxanes Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Vinca Alkaloids Consumption and Growth Rate (2017-2022)

      • 9.2.4 Global Others Consumption and Growth Rate (2017-2022)

    10 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Outlook by Types and Applications to 2028

    • 10.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global APX-3330 Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global BR-297 Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.3 Global Cannabidiol Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.4 Global Dimiracetam Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Platinum Agents Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Taxanes Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.3 Global Vinca Alkaloids Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.4 Global Others Consumption Forecast and Growth Rate (2022-2028)

    11 Global Chemotherapy Induced Peripheral Neuropathy Treatment Import and Export Analysis (Top 5 Countries)

    • 11.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 Chemotherapy Induced Peripheral Neuropathy Treatment Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Competitive Analysis

    • 14.1 Sova Pharmaceuticals Inc

      • 14.1.1 Sova Pharmaceuticals Inc Company Details

      • 14.1.2 Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product and Service

    • 14.2 Immune Pharmaceuticals Inc

      • 14.2.1 Immune Pharmaceuticals Inc Company Details

      • 14.2.2 Immune Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 Immune Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product and Service

    • 14.3 Nemus Bioscience Inc

      • 14.3.1 Nemus Bioscience Inc Company Details

      • 14.3.2 Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product and Service

    • 14.4 WinSanTor

      • 14.4.1 WinSanTor Company Details

      • 14.4.2 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Product and Service

    • 14.5 Apexian Pharma

      • 14.5.1 Apexian Pharma Company Details

      • 14.5.2 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Product and Service

    • 14.6 DermaXon LLC

      • 14.6.1 DermaXon LLC Company Details

      • 14.6.2 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product and Service

    • 14.7 PledPharma

      • 14.7.1 PledPharma Company Details

      • 14.7.2 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.7.3 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Product and Service

    • 14.8 Krenitsky Pharmaceuticals Inc

      • 14.8.1 Krenitsky Pharmaceuticals Inc Company Details

      • 14.8.2 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.8.3 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product and Service

    • 14.9 Aptinyx Inc

      • 14.9.1 Aptinyx Inc Company Details

      • 14.9.2 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.9.3 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product and Service

    • 14.10 Kineta Inc

      • 14.10.1 Kineta Inc Company Details

      • 14.10.2 Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.10.3 Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product and Service

    • 14.11 Regenacy Pharmaceuticals

      • 14.11.1 Regenacy Pharmaceuticals Company Details

      • 14.11.2 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.11.3 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Product and Service

    • 14.12 Asahi Kasei Pharma Corp

      • 14.12.1 Asahi Kasei Pharma Corp Company Details

      • 14.12.2 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.12.3 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Product and Service

    • 14.13 PeriphaGen

      • 14.13.1 PeriphaGen Company Details

      • 14.13.2 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.13.3 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Product and Service

    • 14.14 Metys Pharmaceuticals AG

      • 14.14.1 Metys Pharmaceuticals AG Company Details

      • 14.14.2 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.14.3 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Product and Service

    • 14.15 MAKScientific LLC

      • 14.15.1 MAKScientific LLC Company Details

      • 14.15.2 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.15.3 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of Chemotherapy Induced Peripheral Neuropathy Treatment

    • Figure Chemotherapy Induced Peripheral Neuropathy Treatment Picture

    • Table Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Chemotherapy Induced Peripheral Neuropathy Treatment Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global Chemotherapy Induced Peripheral Neuropathy Treatment Consumption by Country (2017-2022)

    • Figure United States Chemotherapy Induced Peripheral Neuropathy Treatment Consumption and Growth Rate (2017-2022)

    • Table Europe Chemotherapy Induced Peripheral Neuropathy Treatment Consumption and Growth Rate (2017-2022)

    • Figure China Chemotherapy Induced Peripheral Neuropathy Treatment Consumption and Growth Rate (2017-2022)

    • Figure Japan Chemotherapy Induced Peripheral Neuropathy Treatment Consumption and Growth Rate (2017-2022)

    • Figure India Chemotherapy Induced Peripheral Neuropathy Treatment Consumption and Growth Rate (2017-2022)

    • Figure South Korea Chemotherapy Induced Peripheral Neuropathy Treatment Consumption and Growth Rate (2017-2022)

    • Figure Global Chemotherapy Induced Peripheral Neuropathy Treatment Consumption Forecast by Country (2022-2028)

    • Figure United States Chemotherapy Induced Peripheral Neuropathy Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Chemotherapy Induced Peripheral Neuropathy Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure China Chemotherapy Induced Peripheral Neuropathy Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Chemotherapy Induced Peripheral Neuropathy Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Chemotherapy Induced Peripheral Neuropathy Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Chemotherapy Induced Peripheral Neuropathy Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global APX-3330 Consumption and Growth Rate (2017-2022)

    • Figure Global BR-297 Consumption and Growth Rate (2017-2022)

    • Figure Global Cannabidiol Consumption and Growth Rate (2017-2022)

    • Figure Global Dimiracetam Consumption and Growth Rate (2017-2022)

    • Figure Global Platinum Agents Consumption and Growth Rate (2017-2022)

    • Figure Global Taxanes Consumption and Growth Rate (2017-2022)

    • Figure Global Vinca Alkaloids Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global APX-3330 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global BR-297 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Cannabidiol Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Dimiracetam Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Platinum Agents Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Taxanes Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Vinca Alkaloids Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Table Global Chemotherapy Induced Peripheral Neuropathy Treatment Import by Region (Top 5 Countries) (2017-2028)

    • Table Global Chemotherapy Induced Peripheral Neuropathy Treatment Export by Region (Top 5 Countries) (2017-2028)

    • Table Sova Pharmaceuticals Inc (Foundation Year, Company Profile and etc.)

    • Table Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product and Service

    • Table Immune Pharmaceuticals Inc (Foundation Year, Company Profile and etc.)

    • Table Immune Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Immune Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product and Service

    • Table Nemus Bioscience Inc (Foundation Year, Company Profile and etc.)

    • Table Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product and Service

    • Table WinSanTor (Foundation Year, Company Profile and etc.)

    • Table WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Product and Service

    • Table Apexian Pharma (Foundation Year, Company Profile and etc.)

    • Table Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Product and Service

    • Table DermaXon LLC (Foundation Year, Company Profile and etc.)

    • Table DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product and Service

    • Table PledPharma (Foundation Year, Company Profile and etc.)

    • Table PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Product and Service

    • Table Krenitsky Pharmaceuticals Inc (Foundation Year, Company Profile and etc.)

    • Table Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product and Service

    • Table Aptinyx Inc (Foundation Year, Company Profile and etc.)

    • Table Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product and Service

    • Table Kineta Inc (Foundation Year, Company Profile and etc.)

    • Table Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product and Service

    • Table Regenacy Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Product and Service

    • Table Asahi Kasei Pharma Corp (Foundation Year, Company Profile and etc.)

    • Table Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Product and Service

    • Table PeriphaGen (Foundation Year, Company Profile and etc.)

    • Table PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Product and Service

    • Table Metys Pharmaceuticals AG (Foundation Year, Company Profile and etc.)

    • Table Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Product and Service

    • Table MAKScientific LLC (Foundation Year, Company Profile and etc.)

    • Table MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US